Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Stanford Health Care

Response to Immunotherapy in Sclerosing Epithelioid Fibrosarcoma: Case Report and Literature Review.

Response to Immunotherapy in Sclerosing Epithelioid Fibrosarcoma: Case Report and Literature Review. Cureus Koerner, A. S., Zhou, M., Brook, A., Yoon, S. S., Ganjoo, K. N. 2023; 15 (12): e50967

Abstract

Sclerosing epithelioid fibrosarcoma (SEF) is an extremely rare subtype of sarcoma that appears histologically low-grade yet usually has a clinically aggressive course with a high rate of local recurrence and distant metastasis. However, these recurrences and metastases often occur years after initial treatment. Metastases can be to the lung as well as extra-pulmonary sites. In this case report, we discuss a patientwho developed SEF in the deep soft tissue with metastases. This patientunderwent checkpoint inhibitor therapy, with disease response. Thus, SEF is a sarcoma subtype with a unique tumor biology, and immunotherapy may be a promising avenue for treatment.

View details for DOI 10.7759/cureus.50967

View details for PubMedID 38259411